Who buys Zivo stock?

Who buys Zivo stock?

ZIVO stock was bought by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC, and Wells Fargo & Company MN. Company insiders that have bought ZIVO Bioscience stock in the last two years include Christopher D Maggiore, and Nola E Masterson.

What is the Zivo Bioscience (Zivo) earnings report?

ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) announced its earnings results on Monday, May, 11th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.02 million for the quarter.

Will coronavirus (covid-19) affect Zivo Bioscience stock?

ZIVO Bioscience’s stock was trading at $0.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZIVO stock has increased by 2,392.9% and is now trading at $3.49.

What is the expected net proceeds from the offering of Zivo?

ZIVO expects to receive gross proceeds of $13.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with the offering, the Company will effectuate a reverse split of its issued and outstanding common stock at a ratio of 1-for-80.

What is Zivo Bioscience’s mailing address?

ZIVO Bioscience’s mailing address is 2804 ORCHARD LAKE ROAD SUITE 202, KEEGO HARBOR MI, 48320. The biotechnology company can be reached via phone at (248) 452-9866 or via email at [email protected].

What is the closing date for the Zivo IPO?

ZIVO has granted the underwriters a 45-day option to purchase up to an additional 414,000 shares of common stock and/or an additional 414,000 warrants at the public offering price to cover over-allotments, if any. The offering is expected to close on June 2, 2021, subject to customary closing conditions.